Show simple item record

dc.contributor.author Szász, Attila Marcell
dc.contributor.author Győrffy, Balázs
dc.contributor.author Marko-Varga G
dc.date.accessioned 2017-06-06T12:07:58Z
dc.date.available 2017-06-06T12:07:58Z
dc.date.issued 2017
dc.identifier.citation pagination=132-142; journalVolume=64; journalTitle=SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/4274
dc.identifier.uri doi:10.1016/j.semcdb.2016.08.026
dc.description.abstract Current manuscript gives a synopsis of tumor heterogeneity related to patient samples analyzed by proteomics, protein expression analysis and imaging mass spectrometry. First, we discuss the pathophysiologocal background of cancer biology as a multifactorial and challenging diseases. Disease pathology forms the basis for protein target selection. Therefore, histopathological diagnostics and grading of tumors is highlighted. Pathology is the cornerstone of state-of-the-art diagnostics of tumors today both by establishing dignity and - when needed - describing molecular properties of the cancers. Drug development by the pharmaceutical industry utilizes proteomics studies to pinpoint the most relevant targets. Molecular studies profiling affinity-interactions of the protein(s) with targeted small drug molecules to reach efficacy and optimal patient safety are today requested by the FDA and other agencies for new drug development. An understading of basic mechanisms, controlling drug action and drug binding is central, as a new era of personalized medicine becomes an important milestone solution for the healthcare sector as well as the Pharma and Biotech industry. Development of further diagnostic, prognostic and predictive tests will aid current and future treatment of cancer patients. In the paper we present current status of Proteomics that we believe requires attention in order to collectively advance forward in the fight against cancer, addressing the burning opportunities and challenges.
dc.relation.ispartof urn:issn:1084-9521
dc.title Cancer heterogeneity determined by functional proteomics
dc.type Journal Article
dc.date.updated 2017-04-05T11:33:18Z
dc.language.rfc3066 en
dc.identifier.mtmt 3115032
dc.identifier.pubmed 27569188
dc.contributor.department SE/AOK/K/II. Sz. Gyermekgyógyászati Klinika
dc.contributor.institution Semmelweis Egyetem


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account